Buscar
image du produit
Lancet Oncology, The

Suscribirse

Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial - 01/02/22

Doi : 10.1016/S1470-2045(21)00692-6 
Yoon-Koo Kang, ProfMD a, Li-Tzong Chen, ProfMD b, c, Min-Hee Ryu, ProfMD a, Do-Youn Oh, ProfMD d, e, Sang Cheul Oh, MD f, Hyun Cheol Chung, ProfMD g, Keun-Wook Lee, ProfMD h, Takeshi Omori, MD i, Kohei Shitara, MD j, Shinichi Sakuramoto, ProfMD k, Ik-Joo Chung, ProfMD l, Kensei Yamaguchi, MD m, Ken Kato, MD n, Sun Jin Sym, ProfMD o, Shigenori Kadowaki, MD p, Kunihiro Tsuji, MD q, Jen-Shi Chen, MD r, Li-Yuan Bai, MD s, Sung-Yong Oh, MD t, Yasuhiro Choda, MD u, Hisateru Yasui, MD v, Kentaro Takeuchi, MSc w, Yoshinori Hirashima, MD w, Shunsuke Hagihara, MSc x, Narikazu Boku, MD n, ⁎
a Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
b National Institute of Cancer Research, National Health Research Institutes, and National Cheng Kung University Hospital, National Cheng Kung University, Tainan, Taiwan 
c Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan 
d Department of Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea 
e Integrated Major in Innovative Medical Science, Seoul National University Graduate School, Seoul, Korea 
f Division of Hematology and Oncology, Department of Internal Medicine, College of Medicine, Korea University, Seoul, South Korea 
g Division of Medical Oncology, Yonsei Cancer Center, Song-Dang Institute for Cancer Research, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea 
h Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, South Korea 
i Department of Gastroenterological Surgery, Osaka International Cancer Institute, Osaka, Japan 
j Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan 
k Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Hidaka, Japan 
l Department of Hematology-Oncology, Chonnam National University Hwasun Hospital, Chonnam National University College of Medicine, Hwasun, South Korea 
m Department of Gastroenterological Chemotherapy, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan 
n Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan 
o Department of Internal Medicine, Division of Medical Oncology, Gachon University Gil Medical Center, Incheon, South Korea 
p Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan 
q Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan 
r Division of Hematology and Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Chang Gung University, Taoyuan, Taiwan 
s Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, and China Medical University, Taichung, Taiwan 
t Department of Hemato-Oncology, Dong-a University Hospital, Busan, South Korea 
u Department of Surgery, Hiroshima Citizens Hospital, Hiroshima, Japan 
v Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan 
w Department of Oncology Clinical Development Planning, Ono Pharmaceutical, Osaka, Japan 
x Department of Statistical Analysis, Ono Pharmaceutical, Osaka, Japan 

* Correspondence to: Dr Narikazu Boku, Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan Division of Gastrointestinal Medical Oncology National Cancer Center Hospital Tokyo 104-0045 Japan

Summary

Background

The additive or synergistic sustained antitumour effect of immune checkpoint inhibitors in combination with oxaliplatin-based chemotherapy has previously been reported. We investigated the efficacy of nivolumab plus oxaliplatin-based chemotherapy versus placebo plus oxaliplatin-based chemotherapy as first-line therapy for patients with HER2-negative, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer.

Methods

We did a randomised, multicentre, double-blind, placebo-controlled, phase 2–3 trial (ATTRACTION-4) at 130 centres (hospitals, cancer centres, and medical centres) across Japan, South Korea, and Taiwan. We enrolled patients aged 20 years and older with previously untreated (except for neoadjuvant or adjuvant chemotherapy completed ≥180 days before recurrence), HER2-negative, unresectable, advanced or recurrent gastric or gastro-oesophageal junction cancer (regardless of PD-L1 expression), at least one measurable lesion per Response Evaluation Criteria in Solid Tumours guidelines (version 1.1), and a baseline Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Patients were randomly assigned (1:1) to chemotherapy every 3 weeks (intravenous oxaliplatin 130 mg/m2 on day 1 plus either oral S-1 40 mg/m2 [SOX] or oral capecitabine 1000 mg/m2 [CAPOX], twice daily on days 1–14), in addition to either 360 mg nivolumab intravenously every 3 weeks (nivolumab plus chemotherapy group) or placebo (placebo plus chemotherapy group). Randomisation was done using an interactive web response system with block sizes of four and stratified by intensity of PD-L1 expression, ECOG performance status score, disease status, and geographical region. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoints were centrally assessed progression-free survival and overall survival in the intention-to-treat population, which included all randomly assigned patients. Safety was assessed in all patients who received at least one dose of the assigned treatment. This trial is registered with ClinicalTrials.gov, NCT02746796. Trial recruitment is complete and follow-up is ongoing.

Findings

Between March 23, 2017, and May 10, 2018, 724 patients were randomly assigned to treatment: 362 patients to the nivolumab plus chemotherapy group and 362 to the placebo plus chemotherapy group. At the time of data cutoff on Oct 31, 2018, with a median follow-up of 11·6 months (IQR 8·7–14·1), median progression-free survival at a prespecified interim analysis was 10·45 months (95% CI 8·44–14·75) in the nivolumab plus chemotherapy group and 8·34 months (6·97–9·40) in the placebo plus chemotherapy group (hazard ratio [HR] 0·68; 98·51% CI 0·51–0·90; p=0·0007). At the time of data cutoff on Jan 31, 2020, with a median follow-up of 26·6 months (IQR 24·1–29·0), median overall survival at the final analysis was 17·45 months (95% CI 15·67–20·83) in the nivolumab plus chemotherapy group and 17·15 months (15·18–19·65) in the placebo plus chemotherapy group (HR 0·90; 95% CI 0·75–1·08; p=0·26). The most common treatment-related grade 3–4 adverse events were neutrophil count decreased (71 [20%] of 359 patients in the nivolumab plus chemotherapy group vs 57 [16%] of 358 patients in the placebo plus chemotherapy group) and platelet count decreased (34 [9%] vs 33 [9%]). Treatment-related serious adverse events of any grade were observed in 88 (25%) patients in the nivolumab plus chemotherapy group and in 51 (14%) in the placebo plus chemotherapy group, of which the most common was decreased appetite (18 [5%] vs ten [3%]). Six treatment-related deaths occurred: three in the nivolumab plus chemotherapy group (one each of febrile neutropenia, hepatic failure, and sudden death) and three in the placebo plus chemotherapy group (one each of sepsis, haemolytic anaemia, and interstitial lung disease).

Interpretation

Nivolumab combined with oxaliplatin-based chemotherapy significantly improved progression-free survival, but not overall survival, in Asian patients with untreated, HER2-negative, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer, and could potentially be a new first-line treatment option for these patients.

Funding

Ono Pharmaceutical and Bristol-Myers Squibb.

El texto completo de este artículo está disponible en PDF.

Esquema


© 2022  Elsevier Ltd. Reservados todos los derechos.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

    •

  • Contenido

    •

Vol 23 - N° 2

P. 234-247 - février 2022 Regresar al número
Artículo precedente Artículo precedente
  • Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
  • Caicun Zhou, Ziping Wang, Yuping Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Jianhua Chang, Jianhua Chen, Wu Zhuang, Jiuwei Cui, Xueqin Chen, You Lu, Hong Shen, Jingru Wang, Peiqi Li, Mengmeng Qin, Dongmei Lu, Jason Yang
| Artículo siguiente Artículo siguiente
  • Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
  • Arlene O Siefker-Radtke, Andrea Necchi, Se Hoon Park, Jesús García-Donas, Robert A Huddart, Earle F Burgess, Mark T Fleming, Arash Rezazadeh Kalebasty, Begoña Mellado, Sergei Varlamov, Monika Joshi, Ignacio Duran, Scott T Tagawa, Yousef Zakharia, Sydney Akapame, Ademi E Santiago-Walker, Manish Monga, Anne O’Hagan, Yohann Loriot, BLC2001 Study Group, Andrea Necchi, Yohann Loriot, Se Hoon Park, Scott Tagawa, Aude Flechon, Boris Alexeev, Sergey Varlamov, Robert Huddart, Earle Burgess, Arash Rezazadeh, Arlene Siefker-Radtke, Yann Vano, Donatello Gasparro, Alketa Hamzaj, Eugeniy Kopyltsov, Jesus Gracia Donas, Begona Mellado, Omi Parikh, Peter Schatteman, Stephane Culine, Nadine Houédé, Sylvie Zanetta, Gaetano Facchini, Giorgio Scagliotti, Giovanni Schinzari, Jae Lyun Lee, Mikhail Shkolnik, Mark Fleming, Monica Joshi, Peter O’Donnell, Herbert Stöger, Karel Decaestecker, Luc Dirix, Jean Pascal Machiels, Dephine Borchiellini, Remy Delva, Frederic Rolland, Boris Hadaschik, Margitta Retz, Eli Rosenbaum, Umberto Basso, Alessandra Mosca, Hyo Jin Lee, Dong Bok Shin, Cristina Cebotaru, Ignacio Duran, Victor Moreno, Jose Luis Perez Gracia, Alvaro Pinto, Wen-Pin Su, Shian-Shiang Wang, John Hainsworth, Ian Schnadig, Sandhya Srinivas, Nicholas Vogelzang, Wolfgang Loidl, Johannes Meran, Marine Gross Goupil, Florence Joly, Florian Imkamp, Theodor Klotz, Susanne Krege, Matthias May, Wolfgang Schultze-Seemann, Arne Strauss, Uwe Zimmermann, Daniel Keizman, Avivit Peer, Avishai Sella, Rossana Berardi, Ugo De Giorgi, Cora Nanette Sternberg, Sun Young Rha, Iurie Bulat, Adel Izmailov, Vsevolod Matveev, Vladimir Vladimirov, Joan Carles, Albert Font, Maribel Saez, Isabel Syndikus, Kathryn Tarver, Leonard Appleman, John Burke, Nancy Dawson, Sharad Jain, Yousef Zakharia

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta

Aide & support

Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.

Todo el contenido en este sitio: Copyright © 2024 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.